191655-29-5

Upstream product

• 5292-43-3 bromoacetic acid tert-butyl ester 
• 79069-15-1 N-(tert-butyloxycarbonyl)-O-benzyl-L-serinol 
• 23680-31-1 BOC-O-benzyl-L-serine 

Downstream Products

• 1004791-19-8 (Z)-(1S,6R,9aR)-3-[3-methoxy-4-(4-methyl-1H-imidazole-1-yl)benzylidene]-1-methyl-6-(3,4,5-trifluorophenyl)tetrahydro[1,4]oxazino[3,4-c][1,4]oxazine-4-one 
• 1050392-12-5 (Z)-(1R,6R,9aR)-3-[3-methoxy-4-(4-methylimidazol-1-yl)benzylidene]-1-methyl-6-(3,4,5-trifluorophenyl)tetrahydro-[1,4]oxazino[3,4-c][1,4]oxazin-4-one 
• 937816-19-8 (3S,5R)-3-hydroxymethyl-5-(3,4,5-trifluorophenyl)morpholin-4-carboxylic acid 9H-fluoren-9-yl methyl ester 
• 1004791-41-6 (3R,5S)-3-(3,4-difluorophenyl)-5-hydroxymethylmorpholine-4-carboxylic acid 9H-fluorene-9-ylmethyl ester 
• 1004791-42-7 (3R,5R)-3-(3,4-difluorophenyl)-5-(1-hydroxyethyl)morpholine 4-carboxylic acid 9H-fluoren-9-yl methyl ester 
• 1050392-21-6 {(S)-2-benzyloxymethyl-1-[2-(3,4-difluorophenyl)-2-oxoethoxymethyl]ethyl}carbamic acid t-butyl ester 
• 1050392-08-9 (6R,9aR)-1-methyl-6-(3,4,5-trifluorophenyl)tetrahydro-[1,4]oxazino[3,4-c][1,4]oxazin-3,4-dione 
• 1004791-44-9 (1S,6R,9aR)-6-(3,4-difluorophenyl)-1-methyltetrahydro-[1,4]oxazino[3,4-c][1,4]oxazine-3,4-dione 
• 1050392-05-6 1-[(3R,5R)-5-(3,4,5-trifluorophenyl)morpholin-3-yl]ethanol 
• 1004791-43-8 (3R,5R)-3-(3,4-difluorophenyl)-5-(1-hydroxyethyl)morpholine 
• 937400-45-8 [(3S,5R)-5-(3,4-difluorophenyl)morpholine-3-yl]methanol 
• 937400-30-1 {(S)-1-benzyloxymethyl-2-[2-oxo-2-(3,4,5-trifluorophenyl)ethoxy]ethyl}carbamic acid tert-butyl ester 
• 937400-29-8 (S)-3-benzyloxymethyl-5-oxomorpholine-4-carboxylic acid tert-butyl ester 
• 937400-31-2 [(3S,5R)-5-(3,4,5-trifluorophenyl)morpholine-3-yl]methanol 

Relevant academic research and scientific papers

TWO CYCLIC OXOMORPHORIN DERIVATIVES

The present invention relates to a compound represented by formula (I): wherein R1 represents a C1-3 alkyl group, R2 represents a hydrogen atom or a C1-3 alkyl group, Ar represents a phenyl group or the like which may be substituted with 1 to 3 substituents, X represents an oxygen atom or the like, n and m are the same or different and integers of 0 to 2, or a pharmacologically acceptable salt, and use thereof as a medicament.

Polyamide based nucleic acid analogs synthesis of δ-amino acids with nucleic acid bases bearing side chains

Nucleoamino acids of type I-III have been synthesized, which can serve as building blocks for novel polyamide based nucleic acid analogs. Key steps in the syntheses are the alkylation of serinol I and homoserinol 18 with tert-butyl bromoacetate or tert-butyl bromopropionate under phase transfer conditions and the introduction of thymine or uracil into the amino acid side drains by way of a Mitsunobu reaction. Cytosine derivatives were prepared through uracil → cytosine base conversion at the stage of N(δ)-BOC protected amino acid tert-butyl esters.